HRP20210737T1 - Primjena selektivnog inhibitora il-6-trans-signalizacije - Google Patents
Primjena selektivnog inhibitora il-6-trans-signalizacije Download PDFInfo
- Publication number
- HRP20210737T1 HRP20210737T1 HRP20210737TT HRP20210737T HRP20210737T1 HR P20210737 T1 HRP20210737 T1 HR P20210737T1 HR P20210737T T HRP20210737T T HR P20210737TT HR P20210737 T HRP20210737 T HR P20210737T HR P20210737 T1 HRP20210737 T1 HR P20210737T1
- Authority
- HR
- Croatia
- Prior art keywords
- polypeptide dimer
- colitis
- seq
- monomers
- days
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 239000000539 dimer Substances 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 23
- 102000004196 processed proteins & peptides Human genes 0.000 claims 23
- 108090000765 processed proteins & peptides Proteins 0.000 claims 23
- 238000000034 method Methods 0.000 claims 13
- 239000000178 monomer Substances 0.000 claims 9
- 102000004889 Interleukin-6 Human genes 0.000 claims 6
- 108090001005 Interleukin-6 Proteins 0.000 claims 6
- 206010009887 colitis Diseases 0.000 claims 6
- 230000001404 mediated effect Effects 0.000 claims 6
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 4
- 150000001413 amino acids Chemical group 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 108010074051 C-Reactive Protein Proteins 0.000 claims 3
- 102100032752 C-reactive protein Human genes 0.000 claims 3
- 210000000440 neutrophil Anatomy 0.000 claims 3
- 239000013543 active substance Substances 0.000 claims 2
- HDBQZGJWHMCXIL-UHFFFAOYSA-N 3,7-dihydropurine-2-thione Chemical compound SC1=NC=C2NC=NC2=N1 HDBQZGJWHMCXIL-UHFFFAOYSA-N 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009895 Colitis ischaemic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 206010058838 Enterocolitis infectious Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010046851 Uveitis Diseases 0.000 claims 1
- 230000001363 autoimmune Effects 0.000 claims 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 claims 1
- 229960002170 azathioprine Drugs 0.000 claims 1
- 210000001072 colon Anatomy 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 208000027139 infectious colitis Diseases 0.000 claims 1
- 201000008222 ischemic colitis Diseases 0.000 claims 1
- KBOPZPXVLCULAV-UHFFFAOYSA-N mesalamine Chemical compound NC1=CC=C(O)C(C(O)=O)=C1 KBOPZPXVLCULAV-UHFFFAOYSA-N 0.000 claims 1
- 229960004963 mesalazine Drugs 0.000 claims 1
- 230000005855 radiation Effects 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5412—IL-6
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
- C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
Claims (15)
1. Polipeptidni dimer koji sadrži dva monomera, od kojih svaki monomer ima najmanje 90% identičnosti sekvence sa SEQ ID NO: 1, pri čemu monomeri sadrže gp130 D6 domenu koja odgovara aminokiselinama na položajima 585-595 SEQ ID NO:1, zglobnu regiju Fc domene koja sadrži aminokiseline na položajima 609-612 SEQ ID NO:1, a monomeri ne sadrže vezu između gp130 dijela i Fc domene, naznačen time što je za uporabu u liječenju upalne bolesti ili IL-6-posredovanog stanja kod čovjeka, pri čemu se polipeptidni dimer daje u dozi od 60 mg do 1 g.
2. Polipeptidni dimer koji sadrži dva monomera, od kojih svaki monomer ima najmanje 90% identičnosti sekvence sa SEQ ID NO: 1, pri čemu monomeri sadrže gp130 D6 domenu koja odgovara aminokiselinama na položajima 585-595 SEQ ID NO:1, zglobnu regiju Fc domene koja sadrži aminokiseline na položajima 609-612 SEQ ID NO:1, a monomeri ne sadrže vezu između gp130 dijela i Fc domene, naznačen time što je za uporabu u liječenju IL-6-posredovanog stanja kod čovjeka bez značajnog smanjenja broja neutrofila, broja trombocita i/ili razina C-reaktivnog proteina ili bez smanjenja broja neutrofila, broja trombocita i/ili razina C-reaktivnog proteina ispod normalnog raspona u zdravih ispitanika ili pacijenata koji pate od IL-6-posredovanog stanja, pri čemu se polipeptidni dimer daje svakih 7-20 dana, poželjno pri čemu se polipeptidni dimer daje u dozi od 60 mg do 1 g.
3. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 1 ili 2 naznačen time što monomeri imaju SEQ ID NO: 1.
4. The polipeptidni dimer za uporabu u postupku prema bilo kojem od zahtjeva 1-3, naznačen time što doza iznosi od 60 mg do 600 mg.
5. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 1, naznačen time što se polipeptidni dimer daje svakih 7-60 dana, poželjno svakih 7-30 dana.
6. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 5, naznačen time što se polipeptidni dimer daje svakih 7-20 dana.
7. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 1 ili 2, naznačen time što se polipeptidni dimer daje svakih 7 dana ili svakih 14 dana.
8. Polipeptidni dimer za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se polipeptidni dimer daje parenteralno, po mogućnosti intravenozno ili potkožno.
9. Polipeptidni dimer za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što je upalna bolest ili IL-6-posredovano stanje upalna bolest crijeva, poželjno pri čemu je upalna bolest crijeva Crohnova bolest ili ulcerozni kolitis.
10. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 9, naznačen time što liječenje inducira ili održava remisiju upalne bolesti crijeva.
11. The polipeptidni dimer za uporabu u postupku prema bilo kojem od zahtjeva 1-8, naznačen time što je upalna bolest ili IL-6-posredovano stanje reumatoidni artritis, psorijaza, uveitis ili ateroskleroza.
12. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 9, naznačen time što je upalna bolest ili IL-6-posredovano stanje kolitis koji nije povezan s upalnom bolešću crijeva.
13. Polipeptidni dimer za uporabu u postupku prema patentnom zahtjevu 12, naznačen time što je kolitis radijacijski kolitis, divertikularni kolitis, ishemijski kolitis, infektivni kolitis, celijakija, autoimuni kolitis, ili kolitis koji je posljedica koje utječu na debelo crijevo.
14. Polipeptidni dimer za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što se broj neutrofila, broj trombocita i/ili razine C-reaktivnog proteina održavaju u fiziološki normalnom rasponu nakon primjene polipeptidnog dimera.
15. Polipeptidni dimer za uporabu u postupku prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time što liječenje nadalje obuhvaća davanje drugog aktivnog sredstva, poželjno pri čemu je drugo aktivno sredstvo 5-aminosalicilna kiselina, azatioprin, 5-merkaptopurin ili kortikosteroid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462086054P | 2014-12-01 | 2014-12-01 | |
| EP15832692.6A EP3226888B1 (en) | 2014-12-01 | 2015-12-01 | Administration of a selective il-6-trans-signalling inhibitor |
| PCT/IB2015/002459 WO2016087941A1 (en) | 2014-12-01 | 2015-12-01 | Administration of a selective il-6-trans-signalling inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210737T1 true HRP20210737T1 (hr) | 2021-06-11 |
Family
ID=55305021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210737TT HRP20210737T1 (hr) | 2014-12-01 | 2021-05-11 | Primjena selektivnog inhibitora il-6-trans-signalizacije |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11198721B2 (hr) |
| EP (2) | EP3912636A1 (hr) |
| JP (1) | JP6775513B2 (hr) |
| KR (1) | KR20170135819A (hr) |
| CN (1) | CN107223132A (hr) |
| CA (1) | CA2969301A1 (hr) |
| DK (1) | DK3226888T3 (hr) |
| ES (1) | ES2875351T3 (hr) |
| HR (1) | HRP20210737T1 (hr) |
| HU (1) | HUE054742T2 (hr) |
| LT (1) | LT3226888T (hr) |
| MA (2) | MA54761A (hr) |
| MD (1) | MD3226888T2 (hr) |
| MX (1) | MX2017007067A (hr) |
| PL (1) | PL3226888T3 (hr) |
| PT (1) | PT3226888T (hr) |
| RS (1) | RS61947B1 (hr) |
| SI (1) | SI3226888T1 (hr) |
| WO (1) | WO2016087941A1 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
| CN115867345A (zh) * | 2020-06-10 | 2023-03-28 | 辉凌有限公司 | 用于治疗动脉粥样硬化性心血管疾病的药物化合物 |
| WO2022139580A1 (en) | 2020-12-22 | 2022-06-30 | Ferring B.V. | Blood gene expression biomarkers to predict response in patients with inflammatory bowel diseases |
| WO2024011946A1 (en) * | 2022-07-12 | 2024-01-18 | I-Mab Biopharma (Hangzhou) Co., Ltd | Polypeptide dimers for the treatment of systemic sclerosis |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4751180A (en) | 1985-03-28 | 1988-06-14 | Chiron Corporation | Expression using fused genes providing for protein product |
| JPH04218000A (ja) | 1990-02-13 | 1992-08-07 | Kirin Amgen Inc | 修飾ポリペプチド |
| WO1994012520A1 (en) | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US5783672A (en) | 1994-05-26 | 1998-07-21 | Immunex Corporation | Receptor for oncostatin M |
| US6472179B2 (en) | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| DE19941897B4 (de) | 1999-09-02 | 2006-06-14 | GSF - Forschungszentrum für Umwelt und Gesundheit GmbH | IL-6 Rezeptor-Protein, Beta-Kette (gp130) des IL-6 Rezeptor-Proteins, für diese Proteine kodierende DNA, davon abgeleitete RNA, Peptid mit den Aminosäuren 771-811 dieser Beta-Kette oder Teilen davon und deren Verwendungen |
| CA2399832C (en) | 2000-02-11 | 2011-09-20 | Stephen D. Gillies | Enhancing the circulating half-life of antibody-based fusion proteins |
| ATE382636T1 (de) * | 2000-04-21 | 2008-01-15 | Conaris Res Inst Ag | Fusionsproteine, die zwei lösliche gp130 moleküle enthalten |
| AU2002303869B2 (en) | 2001-05-21 | 2007-08-16 | Novartis Ag | Pulmonary administration of chemically modified insulin |
| EP1406929A2 (en) | 2001-07-18 | 2004-04-14 | MERCK PATENT GmbH | Glycoprotein vi fusion proteins |
| AU2002356511A1 (en) | 2001-07-30 | 2003-04-01 | Immunex Corporation | T. reesei phytase enyzmes, polynucleides encoding the enzymes, vectors and host cells thereof, and methods of using |
| JP2004182638A (ja) | 2002-12-03 | 2004-07-02 | Yakult Honsha Co Ltd | 炎症性疾患又は悪性腫瘍の予防治療剤 |
| EP1491554A1 (en) | 2003-06-23 | 2004-12-29 | CONARIS research institute AG | PEGylated soluble gp130-dimers useful as a medicament |
| DE602004014758D1 (de) | 2004-08-27 | 2008-08-14 | Conaris Res Inst Ag | Optimierte Nukleotidsequenzen die für sgp130 kodieren |
| EP1801121A1 (en) | 2005-12-23 | 2007-06-27 | CONARIS research institute AG | Soluble gp130 molecule variants useful as a medicament |
| KR20080090484A (ko) * | 2005-12-30 | 2008-10-08 | 메르크 파텐트 게엠베하 | ＧＰ130 에 대한, ＩＬ-6Ｒα 와 복합체를 형성한 ＩＬ-6의 결합을 방해하는 항-ＩＬ-6 항체 |
| ATE480568T1 (de) * | 2006-06-30 | 2010-09-15 | Conaris Res Inst Ag | Verbesserte sgp 130fc dimere |
| EP2050759A1 (en) | 2007-10-19 | 2009-04-22 | CONARIS research institute AG | Soluble gp 130 muteins with improved binding activity |
| MX2013006234A (es) | 2011-01-06 | 2013-08-01 | Univ Johns Hopkins | Metodo para la produccion de glicoproteinas recombinantes con semivida en circulacion incrementada en celulas de mamifero. |
| MA41116A (fr) | 2014-12-01 | 2017-10-10 | Ferring Bv | Compositions d'inhibiteur de trans-signalisation par l'il-6 sélectif |
-
2015
- 2015-12-01 JP JP2017547084A patent/JP6775513B2/ja active Active
- 2015-12-01 PL PL15832692T patent/PL3226888T3/pl unknown
- 2015-12-01 PT PT158326926T patent/PT3226888T/pt unknown
- 2015-12-01 CN CN201580075096.0A patent/CN107223132A/zh active Pending
- 2015-12-01 MD MDE20170156T patent/MD3226888T2/ro unknown
- 2015-12-01 SI SI201531602T patent/SI3226888T1/sl unknown
- 2015-12-01 EP EP21162245.1A patent/EP3912636A1/en active Pending
- 2015-12-01 RS RS20210709A patent/RS61947B1/sr unknown
- 2015-12-01 DK DK15832692.6T patent/DK3226888T3/da active
- 2015-12-01 US US15/532,092 patent/US11198721B2/en active Active
- 2015-12-01 WO PCT/IB2015/002459 patent/WO2016087941A1/en active Application Filing
- 2015-12-01 KR KR1020177018155A patent/KR20170135819A/ko not_active IP Right Cessation
- 2015-12-01 HU HUE15832692A patent/HUE054742T2/hu unknown
- 2015-12-01 EP EP15832692.6A patent/EP3226888B1/en active Active
- 2015-12-01 ES ES15832692T patent/ES2875351T3/es active Active
- 2015-12-01 LT LTEP15832692.6T patent/LT3226888T/lt unknown
- 2015-12-01 CA CA2969301A patent/CA2969301A1/en active Pending
- 2015-12-01 MX MX2017007067A patent/MX2017007067A/es unknown
- 2015-12-01 MA MA054761A patent/MA54761A/fr unknown
- 2015-12-01 MA MA41114A patent/MA41114B1/fr unknown
-
2021
- 2021-05-11 HR HRP20210737TT patent/HRP20210737T1/hr unknown
- 2021-11-09 US US17/522,320 patent/US20220135652A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20170320932A1 (en) | 2017-11-09 |
| CN107223132A (zh) | 2017-09-29 |
| MX2017007067A (es) | 2018-04-30 |
| SI3226888T1 (sl) | 2021-08-31 |
| DK3226888T3 (da) | 2021-07-12 |
| EP3226888A1 (en) | 2017-10-11 |
| WO2016087941A1 (en) | 2016-06-09 |
| US20220135652A1 (en) | 2022-05-05 |
| EP3912636A1 (en) | 2021-11-24 |
| LT3226888T (lt) | 2021-05-25 |
| RS61947B1 (sr) | 2021-07-30 |
| ES2875351T3 (es) | 2021-11-10 |
| PT3226888T (pt) | 2021-06-02 |
| MA41114B1 (fr) | 2021-06-30 |
| JP2017537155A (ja) | 2017-12-14 |
| PL3226888T3 (pl) | 2021-11-02 |
| CA2969301A1 (en) | 2016-06-09 |
| MD3226888T2 (ro) | 2021-08-31 |
| HUE054742T2 (hu) | 2021-09-28 |
| KR20170135819A (ko) | 2017-12-08 |
| EP3226888B1 (en) | 2021-04-21 |
| MA54761A (fr) | 2021-11-24 |
| JP6775513B2 (ja) | 2020-10-28 |
| US11198721B2 (en) | 2021-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210737T1 (hr) | Primjena selektivnog inhibitora il-6-trans-signalizacije | |
| EA202190377A1 (ru) | Композиции ингибиторов cxcr4 и способы получения и применения | |
| BR112015026549A2 (pt) | forma de dosagem à prova de violação contendo uma ou mais partículas | |
| JP2015007098A5 (hr) | ||
| IL310079A (en) | TIM-3 antagonists for the treatment and diagnosis of cancer | |
| JP2019520550A5 (hr) | ||
| HRP20212010T1 (hr) | Liječenje kolestatskog pruritusa sa seladelparom | |
| BR112017012372A2 (pt) | produto sanitário e agente para tratar o produto sanitário | |
| JP2014527040A5 (hr) | ||
| EA201890082A1 (ru) | Эпитоп антитела | |
| MX2022004572A (es) | Conjugados farmacologicos de ligandos peptidicos biciclicos. | |
| BR112017023867A2 (pt) | métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores | |
| MX2023009423A (es) | Composiciones senoliticas y usos de las mismos. | |
| WO2015200766A3 (en) | Peripherally restricted gaba positive allosteric modulators for the treatment of irritable bowel syndrome and other ailments of the peripheral nervous system | |
| WO2016030334A3 (en) | Methods, agents and compositions for treatment of inflammatory conditions | |
| JP2018532804A5 (hr) | ||
| MX2019012051A (es) | Proteinas para el tratamiento de trastornos de la funcion de la barrera epitelial. | |
| WO2016192819A3 (en) | Modified peptides and their use for treating chronic inflammatory diseases | |
| JP2017520562A5 (hr) | ||
| PH12017550134A1 (en) | Il-37 variants | |
| HRP20210832T1 (hr) | Kombinacija trazodona i gabapentina za liječenje boli | |
| JP2017520554A5 (hr) | ||
| BR112017007306A2 (pt) | Tratamento de combinação compreendendo a administração de 2-amino-3,5,5-triflúor-3,4,5,6- tetra-hidropiridinas | |
| EA202192534A1 (ru) | Системы стабилизации и контролируемого высвобождения для лекарственных средств, нестабильных при стерилизации | |
| Padjen | Drugs used in rheumatic disease |